Skip to main content
. 2014 Nov 27;2:20–24. doi: 10.1016/j.ymgmr.2014.11.007

Table 1.

Immune modulation regimens.

A. Induction
Week 1 2 3 4 5 6 7 8 9 10 11 12 13
Ofatumumab (Ofa) IV 1160 mg/m2/dose Ofa Ofa Ofa Ofa Ofa Every 4 weeks
Bortezomib (BTZ) IV 1.3 mg/m2 days weekly BTZ BTZ BTZ BTZ BTZ BTZ BTZ BTZ
Immunoglobulin (IVIG) 500 mg/kg IVIG every 4 weeksInline graphic
Methotrexate (Mtx) 0.5 mg/kg PO Mtx weeklyInline graphic



B. Intensification
Day 1 2 3 4 8 11 // 22 23 24 25 29 32
Bortezomib (BTZ) IV 1.3 mg/m2 days 1,4, 8 and 11 BTZ BTZ BTZ BTZ BTZ BTZ BTZ BTZ
Dexamethasone (Dex) PO 25 mg/m2/day days 1–4; 21 day cycle Dex Dex Dex Dex Dex Dex Dex Dex
Ofatumumab (Ofa) IV 1160 mg/m2/dose Ofat every 4 weeksInline graphic
Immune globulin (IVIG) 500 mg/kg IVIG every 4 weeksInline graphic
Methotrexate (Mtx) 0.5 mg/kg PO Mtx weeklyInline graphic



C. Maintenance
Ofatumumab (Ofa) IV 1160 mg/m2/dose every 12 weeks for 52 weeks
Immune globulin (IVIG) 500 mg/kg every 4 weeks for 52 weeks
Methotrexate (Mtx) 0.5 mg/kg PO weekly for 52 weeks